interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Remdesivir

Generic competition · all medicines · read 12 November 2026

Is there a generic of Remdesivir, and who makes it?

Remdesivir appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Remdesivir2 dosage-form groups in the Orange Book
0generic makers listed
  1. Remdesivir appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Veklury. No generic is listed as marketed.

20202025203020352040204501brand 2020data datePatent 8318682 listed to expire 22 April 2029Patent RE46762 listed to expire 22 April 2029Patent 8008264 listed to expire 6 September 2029Patent 8318682*PED listed to expire 22 October 2029Patent RE46762*PED listed to expire 22 October 2029Patent 8008264*PED listed to expire 6 March 2030Patent 11492353 listed to expire 8 December 2031Patent 11492353*PED listed to expire 8 June 2032Patent 10065958 listed to expire 18 November 2032Patent 10065958*PED listed to expire 18 May 2033Patent 9724360 listed to expire 29 October 2035Patent 9949994 listed to expire 29 October 2035Patent 9949994*PED listed to expire 29 April 2036Patent 9724360*PED listed to expire 29 April 2036Patent 11382926 listed to expire 16 September 2036Patent 10695361 listed to expire 16 September 2036Patent 11007208 listed to expire 16 September 2036Patent 11007208*PED listed to expire 16 March 2037Patent 11382926*PED listed to expire 16 March 2037Patent 10695361*PED listed to expire 16 March 2037Patent 11266681 listed to expire 10 July 2038Patent 11975017 listed to expire 10 July 2038Patent 10675296 listed to expire 10 July 2038Patent 10675296*PED listed to expire 10 January 2039Patent 11266681*PED listed to expire 10 January 2039Patent 11975017*PED listed to expire 10 January 2039Patent 11975012 listed to expire 28 May 2041Patent 11491169 listed to expire 28 May 2041Patent 11903953 listed to expire 28 May 2041Patent 11491169*PED listed to expire 28 November 2041Patent 11903953*PED listed to expire 28 November 2041Patent 11975012*PED listed to expire 28 November 2041Exclusivity PED to 13 January 2027Exclusivity NPP to 28 February 2027Exclusivity PED to 28 August 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 13 January 2027Exclusivity PED Veklury
  • 28 February 2027Exclusivity NPP Veklury
  • 28 August 2027Exclusivity PED Veklury
  • 22 April 2029Patent 8318682 drug substance
  • 22 April 2029Patent RE46762 drug substance
  • 6 September 2029Patent 8008264 drug substance
  • 22 October 2029Patent 8318682*PED
  • 22 October 2029Patent RE46762*PED
  • 6 March 2030Patent 8008264*PED
  • 8 December 2031Patent 11492353 drug substance
  • 8 June 2032Patent 11492353*PED

24 more patents are listed.

Solution, Intravenous

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

20202025203001brand 2020data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.